Home  |  Contact

Cellosaurus A-375 (CVCL_0132)

Cell line name A-375
Synonyms A 375; A375; A375-MEL; A375-mel; A375mel
Accession CVCL_0132
Resource Identification Initiative To cite this cell line use: A-375 (RRID:CVCL_0132)
Comments Part of: Cancer Cell Line Encyclopedia (CCLE) project.
Part of: COSMIC cell lines project.
Part of: MD Anderson Cell Lines Project.
Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982).
Doubling time: 26.9 +- 6.9 hours (PubMed=29275043); ~32 hours (PBCF).
Microsatellite instability: Stable (MSS) (Sanger).
Omics: Array-based CGH.
Omics: Deep exome analysis.
Omics: Deep proteome analysis.
Omics: Deep RNAseq analysis.
Omics: DNA methylation analysis.
Omics: Protein expression by reverse-phase protein arrays.
Omics: Secretome proteome analysis.
Omics: SNP array analysis.
Omics: Transcriptome analysis.
Sequence variations Homozygous for BRAF p.Val600Glu (c.1799T>A) (ATCC; PubMed=29492214).
Homozygous for CDKN2A p.Glu61Ter (c.181G>T) (p.Gly75Val; c.224G>T) and p.Glu69Ter (c.205G>T) (p.Gly83Val; c.248G>T) (ATCC; PubMed=29492214).
HLA typing Source: PubMed=25960936
Class I
HLA-AA*01:01,02:01
HLA-BB*57:01,44:03
HLA-CC*16:02,06:02
Class II
HLA-DQDQA1*03:02,02:01
DQB1*03:03,03:03
HLA-DRDRB1*04:05,07:01
Disease Amelanotic melanoma (NCIt: C3802)
Species of origin Homo sapiens (Human) (NCBI Taxonomy: 9606)
Hierarchy Children:
CVCL_6546 (4-1.10)CVCL_UD29 (A-375 KRAS p.G13D)CVCL_UD28 (A-375 MEK1 p.Q56P)
CVCL_JF22 (A-375 NRAS p.Q61K)CVCL_LC86 (A375 NRAS (Q61K/+/+))CVCL_2294 (A375-C5)
CVCL_2295 (A375-C6)CVCL_QZ67 (A375-eGFP-Puro)CVCL_QZ68 (A375-Fluc-Neo/eGFP-Puro)
CVCL_QZ69 (A375-Fluc-Neo/hNIS-Puro)CVCL_QZ70 (A375-Fluc-Puro)CVCL_QZ71 (A375-hNIS-Neo/eGFP-Puro)
CVCL_QZ72 (A375-hNIS-Puro)CVCL_QZ73 (A375-iRFP-Neo)CVCL_QZ74 (A375-iRFP-Neo/Fluc-Puro)
CVCL_QZ75 (A375-iRFP-Neo/hNIS-Puro)CVCL_B222 (A375-M)CVCL_X494 (A375-MA1)
CVCL_6233 (A375-P)CVCL_6234 (A375-R)CVCL_5649 (A375-SM)
CVCL_AP96 (A375-VR [2014])CVCL_AQ00 (A375-VR [2015])CVCL_IW10 (A375/R)
CVCL_0136 (A375.S2)CVCL_R745 (A375PF11)CVCL_Y439 (A375S1)
CVCL_KS59 (CellSensor AP1-bla A375)CVCL_KS16 (CellSensor SBE-bla A375)CVCL_6286 (DRO)
Sex of cell Female
Age at sampling 54Y
Category Cancer cell line
STR profile Source(s): ATCC; CLS; Cosmic-CLP; ECACC; PubMed=25877200

Markers:
AmelogeninX
CSF1PO11,12
D13S31711,14
D16S5399
D18S5112,17
D21S1129,30
D3S135815,17
D5S81812
D7S8209
D8S117911,14
FGA23
Penta D9,15
Penta E10,12
TH018
TPOX8,10
vWA16,17
Web pages https://physics.cancer.gov/docs/bioresource/skin/NCI-PBCF-CRL1619_A-375_SOP-508.pdf
http://www.cells-talk.com/index.php/page/copelibrary?key=A375
http://tcpaportal.org/mclp/
Publications

PubMed=4357758; DOI=10.1093/jnci/51.5.1417
Giard D.J., Aaronson S.A., Todaro G.J., Arnstein P., Kersey J.H., Dosik H., Parks W.P.
In vitro cultivation of human tumors: establishment of cell lines derived from a series of solid tumors.
J. Natl. Cancer Inst. 51:1417-1423(1973)

PubMed=327080; DOI=10.1093/jnci/59.1.221
Fogh J., Fogh J.M., Orfeo T.
One hundred and twenty-seven cultured human tumor cell lines producing tumors in nude mice.
J. Natl. Cancer Inst. 59:221-226(1977)

PubMed=833871; DOI=10.1093/jnci/58.2.209
Fogh J., Wright W.C., Loveless J.D.
Absence of HeLa cell contamination in 169 cell lines derived from human tumors.
J. Natl. Cancer Inst. 58:209-214(1977)

PubMed=22282976; DOI=10.1093/carcin/1.1.21
Day R.S. III, Ziolkowski C.H.J., Scudiero D.A., Meyer S.A., Mattern M.R.
Human tumor cell strains defective in the repair of alkylation damage.
Carcinogenesis 1:21-32(1980)

PubMed=6220172
Dracopoli N.C., Fogh J.
Polymorphic enzyme analysis of cultured human tumor cell lines.
J. Natl. Cancer Inst. 70:469-476(1983)

PubMed=6500159; DOI=10.1159/000163283
Gershwin M.E., Lentz D., Owens R.B.
Relationship between karyotype of tissue culture lines and tumorigenicity in nude mice.
Exp. Cell Biol. 52:361-370(1984)

PubMed=3518877; DOI=10.3109/07357908609038260
Fogh J.
Human tumor lines for cancer research.
Cancer Invest. 4:157-184(1986)

PubMed=1832891; DOI=10.1016/0277-5379(91)90277-K
Hansson J., Fichtinger-Schepman A.M.J., Edgren M.R., Ringborg U.
Comparative study of two human melanoma cell lines with different sensitivities to mustine and cisplatin.
Eur. J. Cancer 27:1039-1045(1991)

PubMed=9973934; DOI=10.1016/S0165-4608(98)00122-8
Nelson M.A., Ariza M.E., Yang J.M., Thompson F.H., Taetle R., Trent J.M., Wymer J., Massey-Brown K., Broome-Powell M., Easton J., Lahti J.M., Kidd V.J.
Abnormalities in the p34cdc2-related PITSLRE protein kinase gene complex (CDC2L) on chromosome band 1p36 in melanoma.
Cancer Genet. Cytogenet. 108:91-99(1999)

PubMed=10497214; DOI=10.1074/jbc.274.40.28505
Ariza M.E., Broome-Powell M., Lahti J.M., Kidd V.J., Nelson M.A.
Fas-induced apoptosis in human malignant melanoma cell lines is associated with the activation of the p34(cdc2)-related PITSLRE protein kinases.
J. Biol. Chem. 274:28505-28513(1999)

PubMed=15009714; DOI=10.1046/j.0022-202X.2004.22243.x
Tsao H., Goel V., Wu H., Yang G., Haluska F.G.
Genetic interaction between NRAS and BRAF mutations and PTEN/MMAC1 inactivation in melanoma.
J. Invest. Dermatol. 122:337-341(2004)

PubMed=15467732; DOI=10.1038/sj.onc.1208152
Tanami H., Imoto I., Hirasawa A., Yuki Y., Sonoda I., Inoue J., Yasui K., Misawa-Furihata A., Kawakami Y., Inazawa J.
Involvement of overexpressed wild-type BRAF in the growth of malignant melanoma cell lines.
Oncogene 23:8796-8804(2004)

PubMed=17308088; DOI=10.1158/0008-5472.CAN-06-3311
Shields J.M., Thomas N.E., Cregger M., Berger A.J., Leslie M., Torrice C., Hao H., Penland S., Arbiser J.L., Scott G., Zhou T., Bar-Eli M., Bear J.E., Der C.J., Kaufmann W.K., Rimm D.L., Sharpless N.E.
Lack of extracellular signal-regulated kinase mitogen-activated protein kinase signaling shows a new type of melanoma.
Cancer Res. 67:1502-1512(2007)

PubMed=18172304; DOI=10.1158/0008-5472.CAN-07-1939
Sabatino M., Zhao Y., Voiculescu S., Monaco A., Robbins P., Karai L., Nickoloff B.J., Maio M., Selleri S., Marincola F.M., Wang E.
Conservation of genetic alterations in recurrent melanoma supports the melanoma stem cell hypothesis.
Cancer Res. 68:122-131(2008)

PubMed=19727395; DOI=10.1371/journal.pone.0006888
Wadlow R.C., Wittner B.S., Finley S.A., Bergquist H., Upadhyay R., Finn S., Loda M., Mahmood U., Ramaswamy S.
Systems-level modeling of cancer-fibroblast interaction.
PLoS ONE 4:E6888-E6888(2009)

PubMed=20215515; DOI=10.1158/0008-5472.CAN-09-3458
Rothenberg S.M., Mohapatra G., Rivera M.N., Winokur D., Greninger P., Nitta M., Sadow P.M., Sooriyakumar G., Brannigan B.W., Ulman M.J., Perera R.M., Wang R., Tam A., Ma X.-J., Erlander M., Sgroi D.C., Rocco J.W., Lingen M.W., Cohen E.E.W., Louis D.N., Settleman J., Haber D.A.
A genome-wide screen for microdeletions reveals disruption of polarity complex genes in diverse human cancers.
Cancer Res. 70:2158-2164(2010)

PubMed=21424129; DOI=10.3892/or.2011.1220
Manca A., Sini M.C., Izzo F., Ascierto P.A., Tatangelo F., Botti G., Gentilcore G., Capone M., Mozzillo N., Rozzo C., Cossu A., Tanda F., Palmieri G.
Induction of arginosuccinate synthetase (ASS) expression affects the antiproliferative activity of arginine deiminase (ADI) in melanoma cells.
Oncol. Rep. 25:1495-1502(2011)

PubMed=22460905; DOI=10.1038/nature11003
Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A., Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A., Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J., Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E., Raman P., Shipway A., Engels I.H., Cheng J., Yu G.K., Yu J., Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C., Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C., Liefeld T., MacConaill L., Winckler W., Reich M., Li N., Mesirov J.P., Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L., Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M., Golub T.R., Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.
Nature 483:603-607(2012)

PubMed=23039341; DOI=10.1186/1476-4598-11-75
Byron S.A., Loch D.C., Wellens C.L., Wortmann A., Wu J., Wang J., Nomoto K., Pollock P.M.
Sensitivity to the MEK inhibitor E6201 in melanoma cells is associated with mutant BRAF and wildtype PTEN status.
Mol. Cancer 11:75-75(2012)

PubMed=24581590; DOI=10.1016/j.jdermsci.2014.01.006
Gehrke S., Otsuka A., Huber R., Meier B., Kistowska M., Fenini G., Cheng P., Dummer R., Kerl K., Contassot E., French L.E.
Metastatic melanoma cell lines do not secrete IL-1beta but promote IL-1beta production from macrophages.
J. Dermatol. Sci. 74:167-169(2014)

PubMed=25960936; DOI=10.4161/21624011.2014.954893
Boegel S., Lower M., Bukur T., Sahin U., Castle J.C.
A catalog of HLA type, HLA expression, and neo-epitope candidates in human cancer cell lines.
OncoImmunology 3:E954893-E954893(2014)

PubMed=25485619; DOI=10.1038/nbt.3080
Klijn C., Durinck S., Stawiski E.W., Haverty P.M., Jiang Z., Liu H., Degenhardt J., Mayba O., Gnad F., Liu J., Pau G., Reeder J., Cao Y., Mukhyala K., Selvaraj S.K., Yu M., Zynda G.J., Brauer M.J., Wu T.D., Gentleman R.C., Manning G., Yauch R.L., Bourgon R., Stokoe D., Modrusan Z., Neve R.M., de Sauvage F.J., Settleman J., Seshagiri S., Zhang Z.
A comprehensive transcriptional portrait of human cancer cell lines.
Nat. Biotechnol. 33:306-312(2015)

PubMed=27397505; DOI=10.1016/j.cell.2016.06.017
Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P., Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H., Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H., Deng X., Egan R.K., Liu Q., Mironenko T., Mitropoulos X., Richardson L., Wang J., Zhang T., Moran S., Sayols S., Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P., Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H., Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.
A landscape of pharmacogenomic interactions in cancer.
Cell 166:740-754(2016)

PubMed=28196595; DOI=10.1016/j.ccell.2017.01.005
Li J., Zhao W., Akbani R., Liu W., Ju Z., Ling S., Vellano C.P., Roebuck P., Yu Q., Eterovic A.K., Byers L.A., Davies M.A., Deng W., Gopal Y.N.V., Chen G., von Euw E.M., Slamon D.J., Conklin D., Heymach J.V., Gazdar A.F., Minna J.D., Myers J.N., Lu Y., Mills G.B., Liang H.
Characterization of human cancer cell lines by reverse-phase protein arrays.
Cancer Cell 31:225-239(2017)

PubMed=29275043; DOI=10.1016/j.jprot.2017.12.013
Liberato T., Pessotti D.S., Fukushima I., Kitano E.S., Serrano S.M.T., Zelanis A.
Signatures of protein expression revealed by secretome analyses of cancer associated fibroblasts and melanoma cell lines.
J. Proteomics 174:1-8(2018)

PubMed=29492214; DOI=10.18632/oncotarget.23989
Sini M.C., Doneddu V., Paliogiannis P., Casula M., Colombino M., Manca A., Botti G., Ascierto P.A., Lissia A., Cossu A., Palmieri G.
Genetic alterations in main candidate genes during melanoma progression.
Oncotarget 9:8531-8541(2018)

Cross-references
Cell line collections ATCC; CRL-1619
ATCC; CRL-7904 - Discontinued
BCRC; 60039
BCRJ; 0278
CLS; 300110/p852_A-375
ECACC; 88113005
IZSLER; BS TCL 88
KCB; KCB 99003YJ
NCBI_Iran; C136
Cell line databases/resources CLDB; cl198
CLDB; cl199
CCLE; A375_SKIN
CCRID; 3111C0001CCC000126
CCRID; 3111C0001CCC000327
CCRID; 3131C0001000700004
CCRID; 3131C0001000700155
CGH-DB; 9313-4
Cosmic-CLP; 906793
GDSC; 906793
IGRhCellID; A375
LINCS_HMS; 50060
LINCS_LDP; LCL-1235
Lonza; 970
Ontologies BTO; BTO:0002806
CLO; CLO_0001544
CLO; CLO_0001581
CLO; CLO_0001582
EFO; EFO_0002103
MCCL; MCC:0000024
Biological sample resources BioSample; SAMN03472142
BioSample; SAMN05292441
ENCODE; ENCBS606AAA
ENCODE; ENCBS607AAA
Chemistry resources ChEMBL-Cells; CHEMBL3308077
ChEMBL-Targets; CHEMBL613859
ChEMBL-Targets; CHEMBL1075388
Gene expression databases ArrayExpress; E-MTAB-2706
ArrayExpress; E-MTAB-2770
ArrayExpress; E-MTAB-3610
GEO; GSM206443
GEO; GSM218051
GEO; GSM274681
GEO; GSM276771
GEO; GSM555173
GEO; GSM827158
GEO; GSM886854
GEO; GSM887919
GEO; GSM952580
GEO; GSM1092559
GEO; GSM1138787
GEO; GSM1374382
GEO; GSM1669582
Other Wikidata; Q54605986
Polymorphism and mutation databases Cosmic; 686480
Cosmic; 687431
Cosmic; 706114
Cosmic; 876698
Cosmic; 888861
Cosmic; 897482
Cosmic; 897735
Cosmic; 905226
Cosmic; 906793
Cosmic; 928688
Cosmic; 933003
Cosmic; 1006556
Cosmic; 1022280
Cosmic; 1054855
Cosmic; 1132587
Cosmic; 1155278
Cosmic; 1211162
Cosmic; 1303032
Cosmic; 1458961
Cosmic; 1459655
Cosmic; 1477406
Cosmic; 1481413
Cosmic; 1507620
Cosmic; 1537486
Cosmic; 1555009
Cosmic; 1669118
Cosmic; 1812178
Cosmic; 1888914
Cosmic; 1890486
Cosmic; 1989294
Cosmic; 1995332
Cosmic; 2036699
Cosmic; 2230112
Cosmic; 2233660
Cosmic; 2479252
Proteomic databases PRIDE; PXD001485
PRIDE; PXD004343